Continuous intraperitoneal insulin infusion: an alternative route for insulin delivery in type 1 diabetes

  • S. Pasquini
  • G. Da Prato
  • G. Tonolo
  • E. Bonora
  • M. TrombettaEmail author
Case Report


Continuous intraperitoneal insulin infusion (CIPII) with implantable pump has been employed for almost 30 years as an alternative route for insulin delivery when SC insulin therapy has failed [1]. CIPII mimics physiology more closely than standard therapies because most of the insulin is absorbed through the portal venous system. This route allows a faster, after meal, glucose normalization with reproducible and more predictable insulin profiles even than continuous subcutaneous insulin infusion (CSII); it not only improves hepatic uptake and lowers peripheral plasma insulin levels, but also optimizes glucagon secretion and hepatic glucose production. The current uses of CIPII are severe SC insulin resistance, poor glycemic control with high daily insulin doses, severe hypoglycemia during SC insulin therapy, skin disorders, SC site issues, lipoatrophy with SC insulin and “brittle diabetes” [2].

Case presentation

A 42-year-old Italian woman with type 1 diabetes was admitted...


Compliance with ethical standards

Conflict of interest

The authors declare no competing interests for this manuscript.

Ethical statement

The patient agreed to the description of her clinical story, anonymously.

Informed consent

The patient has given her informed consent for the case report to be published, preserving anonymity.


  1. 1.
    Renard E, Schaepelynck-Bélicar P, EVADIAC Group (2007) Implantable insulin pumps: a position statement about their clinical use. Diabetes Metab 33:158–166CrossRefPubMedGoogle Scholar
  2. 2.
    Garcia-Verdugo R, Erbach M, Schnell O (2017) A new optimized percutaneous access system for CIPII. J Diabetes Sci Technol 11(4):814–821CrossRefPubMedPubMedCentralGoogle Scholar
  3. 3.
    Shapiro AM, Pokrywczynska M, Ricordi C (2017) Clinical pancreatic islet transplantation. Nat Rev Endocrinol 13(5):268–277CrossRefPubMedGoogle Scholar
  4. 4.
    Radermecker RP, Renard E, Scheen AJ (2009) Circulating insulin antibodies: influence of continuous subcutaneous or intraperitoneal insulin infusion, and impact on glucose control. Diabetes Metab Res Rev 25(6):491–501CrossRefPubMedGoogle Scholar
  5. 5.
    Logtenberg SJ, Kleefstra N, Houweling ST, Groenier KH, Gans RO, Bilo HJ (2010) Health-related quality of life, treatment satisfaction, and costs associated with intraperitoneal versus subcutaneous insulin administration in type 1 diabetes: a randomised controlled trial. Diabetes Care 33:1169–1172CrossRefPubMedPubMedCentralGoogle Scholar

Copyright information

© Springer-Verlag Italia S.r.l., part of Springer Nature 2019

Authors and Affiliations

  • S. Pasquini
    • 1
  • G. Da Prato
    • 1
  • G. Tonolo
    • 2
  • E. Bonora
    • 1
  • M. Trombetta
    • 1
    Email author
  1. 1.Division of Endocrinology, Diabetes and Metabolic Diseases, Department of MedicineUniversity of VeronaVeronaItaly
  2. 2.SC Diabetologia Aziendale, ASSLOlbiaItaly

Personalised recommendations